These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37690089)

  • 1. Development of a Chimeric Protein BiPPB-mIFNγ-tTβRII for Improving the Anti-Fibrotic Activity in Vivo by Targeting Fibrotic Liver and Dual Inhibiting the TGF-β1/Smad Signaling Pathway.
    Dong Y; Wang X; Xu L; Li X; Dai H; Mao X; Chu Y; Yuan X; Liu H
    Protein J; 2023 Dec; 42(6):753-765. PubMed ID: 37690089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted truncated TGF-β receptor type II delivery to fibrotic liver by PDGFβ receptor-binding peptide modification for improving the anti-fibrotic activity against hepatic fibrosis in vitro and in vivo.
    Huang Z; Ding M; Dong Y; Ma M; Song X; Liu Y; Gao Z; Guan H; Chu Y; Feng H; Wang X; Liu H
    Int J Biol Macromol; 2021 Oct; 188():941-949. PubMed ID: 34389395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered fibrotic liver-targeted truncated transforming growth factor β receptor type II variant for superior anti-liver fibrosis therapy.
    Ma M; Wang X; Liu X; Han Y; Chu Y; Guan Y; Liu H
    Arch Pharm Res; 2023 Mar; 46(3):177-191. PubMed ID: 36905489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDGFβ receptor-targeted delivery of truncated transforming growth factor β receptor type II for improving the in vitro and in vivo anti-renal fibrosis activity via strong inactivation of TGF-β1/Smad signaling pathway.
    Wang B; Wang X; Dong Y; Liu X; Xu L; Liu Y; Wu Y; Wang C; Liu H
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):237-252. PubMed ID: 37401970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting delivery of a novel TGF-β type I receptor-mimicking peptide to activated hepatic stellate cells for liver fibrosis therapy via inhibiting the TGF-β1/Smad and p38 MAPK signaling pathways.
    Liu X; Wang X; Xu L; Fan J; Yuan Q; Zhang F; Liu J; Qiu X; Li Y; Xia C; Liu H
    Eur J Pharmacol; 2024 Aug; 977():176708. PubMed ID: 38843945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression, purification, and evaluation of in vivo anti-fibrotic activity for soluble truncated TGF-β receptor II as a cleavable His-SUMO fusion protein.
    Wang X; Li Y; Li X; Yan L; Guan H; Han R; Han Y; Gui J; Xu X; Dong Y; Liu H
    World J Microbiol Biotechnol; 2018 Nov; 34(12):181. PubMed ID: 30474742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo.
    Bansal R; Prakash J; De Ruiter M; Poelstra K
    J Control Release; 2014 Apr; 179():18-24. PubMed ID: 24491909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted recombinant fusion proteins of IFNγ and mimetic IFNγ with PDGFβR bicyclic peptide inhibits liver fibrogenesis in vivo.
    Bansal R; Prakash J; De Ruiter M; Poelstra K
    PLoS One; 2014; 9(2):e89878. PubMed ID: 24587093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery of type I TGF-β receptor-mimicking peptide to fibrotic kidney for improving kidney fibrosis therapy via enhancing the inhibition of TGF-β1/Smad and p38 MAPK pathways.
    Wang X; Liu X; Xu L; Li Y; Zheng B; Xia C; Wang J; Liu H
    Int Immunopharmacol; 2024 Aug; 137():112483. PubMed ID: 38880023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physalin D attenuates hepatic stellate cell activation and liver fibrosis by blocking TGF-β/Smad and YAP signaling.
    Xiang D; Zou J; Zhu X; Chen X; Luo J; Kong L; Zhang H
    Phytomedicine; 2020 Nov; 78():153294. PubMed ID: 32771890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Puerarin, isolated from Pueraria lobata (Willd.), protects against hepatotoxicity via specific inhibition of the TGF-β1/Smad signaling pathway, thereby leading to anti-fibrotic effect.
    Xu L; Zheng N; He Q; Li R; Zhang K; Liang T
    Phytomedicine; 2013 Oct; 20(13):1172-9. PubMed ID: 23856441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganoderma lucidum polysaccharide inhibits HSC activation and liver fibrosis via targeting inflammation, apoptosis, cell cycle, and ECM-receptor interaction mediated by TGF-β/Smad signaling.
    Chen C; Chen J; Wang Y; Fang L; Guo C; Sang T; Peng H; Zhao Q; Chen S; Lin X; Wang X
    Phytomedicine; 2023 Feb; 110():154626. PubMed ID: 36603342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-497 induced by Clonorchis sinensis enhances the TGF-β/Smad signaling pathway to promote hepatic fibrosis by targeting Smad7.
    Zhou QY; Yang HM; Liu JX; Xu N; Li J; Shen LP; Zhang YZ; Koda S; Zhang BB; Yu Q; Chen JX; Zheng KY; Yan C
    Parasit Vectors; 2021 Sep; 14(1):472. PubMed ID: 34521449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming growth factor beta-1 upregulates glucose transporter 1 and glycolysis through canonical and noncanonical pathways in hepatic stellate cells.
    Zhou MY; Cheng ML; Huang T; Hu RH; Zou GL; Li H; Zhang BF; Zhu JJ; Liu YM; Liu Y; Zhao XK
    World J Gastroenterol; 2021 Oct; 27(40):6908-6926. PubMed ID: 34790014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morin attenuates diethylnitrosamine-induced rat liver fibrosis and hepatic stellate cell activation by co-ordinated regulation of Hippo/Yap and TGF-β1/Smad signaling.
    Perumal N; Perumal M; Halagowder D; Sivasithamparam N
    Biochimie; 2017 Sep; 140():10-19. PubMed ID: 28552397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-β1/Smad signaling pathway.
    Ni XX; Li XY; Wang Q; Hua J
    J Physiol Biochem; 2021 Feb; 77(1):35-45. PubMed ID: 33188625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvianolic acid B exerts anti-liver fibrosis effects via inhibition of MAPK-mediated phospho-Smad2/3 at linker regions in vivo and in vitro.
    Wu C; Chen W; Ding H; Li D; Wen G; Zhang C; Lu W; Chen M; Yang Y
    Life Sci; 2019 Dec; 239():116881. PubMed ID: 31678285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liuweiwuling tablets attenuate BDL-induced hepatic fibrosis via modulation of TGF-β/Smad and NF-κB signaling pathways.
    Liu H; Dong F; Li G; Niu M; Zhang C; Han Y; He L; Yin P; Wang B; Sang X; Li R; Wang J; Bai Z; Xiao X
    J Ethnopharmacol; 2018 Jan; 210():232-241. PubMed ID: 28864168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment.
    Chen L; Yang T; Lu DW; Zhao H; Feng YL; Chen H; Chen DQ; Vaziri ND; Zhao YY
    Biomed Pharmacother; 2018 May; 101():670-681. PubMed ID: 29518614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chrysophanol ameliorates renal interstitial fibrosis by inhibiting the TGF-β/Smad signaling pathway.
    Dou F; Ding Y; Wang C; Duan J; Wang W; Xu H; Zhao X; Wang J; Wen A
    Biochem Pharmacol; 2020 Oct; 180():114079. PubMed ID: 32511988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.